Author: admin

STOCKHOLM, Feb. 20, 2025 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic and its partner Bristol Myers Squibb (NYSE: BMY) have received clearance from the U.S. Federal Trade Commission (FTC) for BioArctic to out-license its PyroGlutamate-amyloid-bet

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: